Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Phase 2 Unknown 32 enrolled Seoul National University Hospital

NaSingle-groupOpen-labelTreatment

Summary

To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.

Timeline

Start: 2013-06
Primary completion: 2021-08
Completion: 2021-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Antithrombin III	Protein / enzyme biologic	500 iu	—

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Summary

Timeline

Drugs

Indications